Eterna Therapeutics raises $7.7M via private placement of units with warrants

Ernexa Therapeutics Inc.

Offered 2,184,950 units at $3.53 each, each unit consisting of one share and two warrants exercisable at $3.28 per share for five-and-a-half years.
Insiders Chairman Charles Cherington and director Nicholas Singer participated on same terms as other investors.
Closing expected December 2, 2022; net proceeds to be used for general working capital.
Warrants exercisable six months after closing, with beneficial ownership limitations of 4.99% (adjustable to 9.99%).
Securities offered under Section 4(a)(2) and Regulation D; resale registration rights to be filed within 30 days of S-3 eligibility.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Ernexa Therapeutics Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $ 7.7 million (effective 2022-11-23).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Value: approximately $ 7.7 million
Effective: 2022-11-23

Exact text from the filing

On November 23, 2022, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain investors (the “ Purchasers ”) providing for the private placement (the “ Private Placement ”) to the Purchasers of an aggregate of 2,184,950 units (collectively, the “ Units ”), each Unit consisting of (i) one share of the Company’s common stock, par value $0.005 per share (“ Common Stock ”) and (ii) two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share (the “ Warrants ”), for an aggregate purchase price of approximately $ 7.7 million

View on SEC.gov

Browse all material agreements →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-043061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.